Next Article in Journal / Special Issue
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
Previous Article in Journal
Zebrafish Models of Rare Hereditary Pediatric Diseases
Previous Article in Special Issue
Epigenetic Regulation of ATP-Binding Cassette Protein A1 (ABCA1) Gene Expression: A New Era to Alleviate Atherosclerotic Cardiovascular Disease
Article Menu
Issue 2 (June) cover image

Export Article

An updated version is available. Download PDF

Correction published on 7 July 2018, see Diseases 2018, 6(3), 61.

Open AccessFeature PaperReview
Diseases 2018, 6(2), 44; https://doi.org/10.3390/diseases6020044

Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment

Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
*
Author to whom correspondence should be addressed.
Received: 3 May 2018 / Revised: 22 May 2018 / Accepted: 22 May 2018 / Published: 24 May 2018
Full-Text   |   PDF [296 KB, uploaded 27 July 2018]

Abstract

Dyslipidemia is a major risk factor for cardiovascular disease (CVD), which is the leading cause of morbidity and mortality in type 2 diabetes (T2DM). Statins have played a crucial role in its management, but residual risk remains since many patients cannot achieve their desired low-density lipoprotein cholesterol (LDL-C) level and up to 20% of patients are statin-intolerant, experiencing adverse events perceived to be caused by statins, most commonly muscle symptoms. Recently, great advances have been made in nonstatin treatment with ezetimibe, a cholesterol absorption inhibitor, and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs), all showing a proven benefit with an excellent safety profile in cardiovascular outcome trials. This review summarizes the key aspects and the evolving role of these agents in the management of dyslipidemia in patients with T2DM, along with a brief introduction of novel drugs currently in development. View Full-Text
Keywords: dyslipidemia; type 2 diabetes; PCSK9; nonstatin dyslipidemia; type 2 diabetes; PCSK9; nonstatin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sugiyama, K.; Saisho, Y. Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. Diseases 2018, 6, 44.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top